Chronic Myeloid Leukemia (CML) Treatment Market By Type (Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy and Stem Cell Transplant), - Growth, Share, Opportunities & Competitive Analysis, 2016 -2023

The report titled “Chronic Myeloid Leukemia (CML) Treatment Market- Growth, Future Prospects, and Competitive Analysis, 2016 – 2023” offers strategic insights into the overall chronic myeloid leukemia (CML) treatment market along with the market size and estimates for the duration 2013 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of drugs, and different geographies. According to the Leukemia CARE, Chronic myeloid leukaemia (CML) is a form of blood cancer, which affects the white blood cells known as myeloid cells. It is a slowly progressing form of leukaemia. In CML the bone marrow carries out overproduction of white cells or granulocytes which steadily crowd the bone marrow and ultimately interfering with normal blood cell production. There are no specific signs or symptoms which would allow a diagnosis of CML to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. CML accounts for 15% of all leukemias in adults and approximately 8,220 new cases of CML will be diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 populations.

The market experts suggest that, CML is not considered curable with standard treatments; with the possible exception of stem cell transplants in a small number of younger and/or fitter patients. A new class of drugs called tyrosine kinases (TKIs) or BCR-ABL inhibitors has transformed treatment of CML. Currently existing BCR-ABL inhibitors form the stronghold of CML treatment comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been recently approved for market inclusion. A few published reports exhibit that nilotinib and dasatinib have high efficacy than imatinib in first-line chronic-phase CML (CML-CP), allowing more patients to get effective results, comparatively more rapid responses related with enhanced results.

The geographical segmentation comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.

The chronic myeloid leukaemia (CML) market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, Otsuka Pharmaceutical Co., Ltd. and others.

For the purpose of this study, the global chronic myeloid leukemia (CML) market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Chronic Myeloid Leukemia (CML) Treatment Market

In base year 2015, North America was observed as the leading geographical region in chronic myeloid leukemia treatment market due to rising diagnosis rate of chronic myeloid leukemia, market entry of novel targeted drug therapies and organized medical insurance environment. The American Cancer Society's estimates that in year 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people will die of CML (570 men and 500 women). According to research study published in Blood Journal stated that, the constant research carried out on chronic myelogenous leukemia (CML) treatment resulted into USFDA approval of 3 drugs in 2012 for the treatment of CML: bosutinib, ponatinib, and omacetaxine. This is in addition to 3 others approved in the last decade: imatinib, dasatinib, and nilotinib. In 2013, it was observed that 3 new drugs approved have been priced at high levels: ponatinib at US$ 138,000 per year, omacetaxine at US$ 28,000 for induction and US$ 14,000 per maintenance course, and bosutinib at ∼US$ 118,000 per year. Cancer drug prices vary widely in different geographic regions. This supports the fact that drug prices reflect geopolitical and socioeconomics dynamics of the region unrelated to the cost of drug development. In the United States, prices represent the extreme end of high prices, a reflection of a “free market economy” and the notion that “one cannot put a price on a human life,” as well as a failure of government and insurers to more actively negotiate pricing for anticancer and other pharmaceuticals, in contrast to practices in other parts of the world. Overall CML treatment market is growing slowly but upcoming drug approvals are expected to boost the market.

Choose License Type
Published Date:  Sep 2016
Category:  Pharmaceuticals
Report ID:   58082
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Connect With Us
+1-408-641-3282
24/7 Research Support